A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Intervencionista
Fase 3
Sun Yat-sen University Cancer Center
Patrocinador: Shandong Suncadia Medicine
Última actualización: 26 de enero de 2026 Aviso: La información proviene de registros públicos y puede no reflejar cambios en tiempo real en el centro local.
This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.
Categoría de tratamiento
Otros medicamentos, Terapia hormonal, Terapia dirigida
1. Women aged 18 to 75 years old (including both values).
2. ECOG Physical Strength Status (PS) : 0 to 1 point.
3. Patients with locally advanced or metastatic breast cancer confirmed by histology.
4. Patients previously received 1-2 lines of endocrine therapy.
5. Expected survival > 6 months.
6. The functional level of the organs must meet the requirements.
7. Subjects that voluntarily participate in this clinical trial, be willing and able to abide by the procedures related to clinical visits and research, understand the research procedures and have signed the informed consent.
Criterios de exclusión
1. Patients with rapid disease progress and investigators determine that endocrine therapy is not suitable or tolerant.
2. A history of severe clinical cardiovascular diseases.
3. Patients with uncontrollable tumor-related pain as judged by investigators.
4. Severe infection exists within 4 weeks before the first study administration.
5. Patients with clinically significant endometrial abnormalities.
6. Untreated active hepatitis.
7. Patients known to be allergic to HRS-8080 components.
8. Pregnant and lactating women, or those planning to become pregnant during the study period.
¿Cree usted que este ensayo clínico se muestra por error?
Detalles del diseño
AsignaciónRandomized
Modelo de intervenciónParallel Assignment
EnmascaramientoNone (Open Label)
Número a inscribir240
Brazos e Intervenciones
Brazos
Intervenciones
Tipo: Experimental
Descripción:
Intervenciones:
HRS-8080 Tablet
Fulvestrant injection
Exemestane tablets
Everolimus Tablets
Anastrozole Tablets
Letrozole Tablets
Medidas de resultado
Medidas de resultado primarias
Progression free survival (PFS) evaluated by the blinded independent central review (BICR).Approximately 2 years.
Medidas de resultado secundarias
Overall response rate (ORR).Approximately 2 years.
Clinical benefit rate (CBR).Approximately 2 years.
Duration of response (DOR).Approximately 2 years.
Overall survival (OS).Approximately 3 years.
Adverse events (AEs).Approximately 2 years.
Serious adverse events (SAEs).Approximately 2 years.
Progression free survival (PFS) evaluated by investigators.Approximately 2 years.
Guardar ensayo
Compartir ensayo
Descargar ensayo
¿Cree usted que este ensayo clínico se muestra por error?